Trial Outcomes & Findings for Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine (NCT NCT06412965)
NCT ID: NCT06412965
Last Updated: 2025-01-13
Results Overview
Physicians responded as "Yes" or "No" if participants failed to achieve pain freedom within 2 hours post dose. In this outcome measure, number of participants were reported according to physicians' responses. Participant who failed to achieve pain freedom at 2 hours post dose on more than half of the occasion were reported in this outcome measure.
COMPLETED
528 participants
2 hours post dose (from the data collected retrospectively)
2025-01-13
Participant Flow
Data was extracted from Adelphi Real World (ARW) Migraine VII Disease Specific Programme (DSP) 2022 database. Participants diagnosed with migraine and prescribed rimegepant or triptans as an acute treatment for their migraine in the US, were recruited into the Migraine VII DSP US between May 2022 and November 2022. This retrospective observational study comprised secondary data analysis of DSP data.
Participant milestones
| Measure |
Rimegepant
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Overall Study
STARTED
|
91
|
437
|
|
Overall Study
COMPLETED
|
91
|
437
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Number Analyzed = Number of participants who were evaluable and had non-missing values.
Baseline characteristics by cohort
| Measure |
Rimegepant
n=91 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=437 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Total
n=528 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
39.01 Years
STANDARD_DEVIATION 13.11 • n=91 Participants
|
38.98 Years
STANDARD_DEVIATION 13.4 • n=437 Participants
|
38.99 Years
STANDARD_DEVIATION 13.34 • n=528 Participants
|
|
Sex: Female, Male
Female
|
66 Participants
n=89 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
309 Participants
n=437 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
375 Participants
n=526 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
|
Sex: Female, Male
Male
|
23 Participants
n=89 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
128 Participants
n=437 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
151 Participants
n=526 Participants • Number Analyzed = Number of participants who were evaluable and had non-missing values.
|
|
Race/Ethnicity, Customized
White/Caucasian
|
65 Participants
n=91 Participants
|
304 Participants
n=437 Participants
|
369 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
African American
|
12 Participants
n=91 Participants
|
65 Participants
n=437 Participants
|
77 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
Native American
|
1 Participants
n=91 Participants
|
1 Participants
n=437 Participants
|
2 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
Asian (Indian subcontinent)
|
0 Participants
n=91 Participants
|
8 Participants
n=437 Participants
|
8 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
South-East Asian
|
1 Participants
n=91 Participants
|
8 Participants
n=437 Participants
|
9 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
Asian (other)
|
2 Participants
n=91 Participants
|
8 Participants
n=437 Participants
|
10 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
Hispanic / Latino / Latina
|
8 Participants
n=91 Participants
|
38 Participants
n=437 Participants
|
46 Participants
n=528 Participants
|
|
Race/Ethnicity, Customized
Middle Eastern
|
2 Participants
n=91 Participants
|
8 Participants
n=437 Participants
|
10 Participants
n=528 Participants
|
PRIMARY outcome
Timeframe: 2 hours post dose (from the data collected retrospectively)Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Physicians responded as "Yes" or "No" if participants failed to achieve pain freedom within 2 hours post dose. In this outcome measure, number of participants were reported according to physicians' responses. Participant who failed to achieve pain freedom at 2 hours post dose on more than half of the occasion were reported in this outcome measure.
Outcome measures
| Measure |
Rimegepant
n=86 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=384 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective)
Yes
|
23 Participants
|
167 Participants
|
|
Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective)
No
|
63 Participants
|
217 Participants
|
PRIMARY outcome
Timeframe: 2 hours post dose (from the data collected retrospectively)Population: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Number of participants who reported migraine pain freedom within 2 hours post dosing in 0 out of every 5 attacks, 1 out of every 5 attacks, 2 out of every 5 attacks, 3 out of every 5 attacks, 4 out of every 5 attacks, or 5 out of every 5 attacks were recorded. Success was defined as responses to '4 out of every 5 attacks' or '5 out of every 5 attacks' combined. In this outcome measure, number of participants with 'success' were reported as per participants' responses. Participant who reported migraine pain freedom (success) at 2 hours post dose on more than half of occasion were reported in this outcome measure.
Outcome measures
| Measure |
Rimegepant
n=29 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=106 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective)
|
22 Participants
|
67 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study.
Physicians' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to physicians' responses.
Outcome measures
| Measure |
Rimegepant
n=91 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=437 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Extremely satisfied
|
55 Participants
|
103 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Satisfied
|
31 Participants
|
276 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Slightly satisfied
|
2 Participants
|
33 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Neither satisfied nor dissatisfied
|
0 Participants
|
12 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Slightly dissatisfied
|
2 Participants
|
10 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Dissatisfied
|
1 Participants
|
2 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective)
Extremely dissatisfied
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Physicians' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure number of participants were reported per each reason according to physicians' responses. There could be more than 1 reason for lack of satisfaction per participant.
Outcome measures
| Measure |
Rimegepant
n=5 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=58 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Number of side effects experienced
|
0 Participants
|
8 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Lack of efficacy
|
3 Participants
|
26 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Slow onset of action
|
0 Participants
|
13 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Efficacy diminished over time
|
0 Participants
|
17 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Severity of side effects experienced
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Mode of administration
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
The number of prescribed acute treatments
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
The treatment is costly for the participant
|
2 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective)
Other
|
1 Participants
|
7 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Participants' satisfaction with current acute treatment for migraine was recorded and classified as extremely satisfied, satisfied, slightly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied, dissatisfied and extremely dissatisfied. In this outcome measure number of participants were reported per each category according to participants' responses.
Outcome measures
| Measure |
Rimegepant
n=29 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=103 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Extremely satisfied
|
17 Participants
|
23 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Satisfied
|
11 Participants
|
57 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Slightly satisfied
|
0 Participants
|
11 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Neither satisfied nor dissatisfied
|
1 Participants
|
5 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Slightly dissatisfied
|
0 Participants
|
5 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Dissatisfied
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective)
Extremely dissatisfied
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Participants' reported reasons for lack of satisfaction with current acute treatment. In this outcome measure, number of participants were reported per each reason according to participants' responses. There could be more than 1 reason for lack of satisfaction per participant.
Outcome measures
| Measure |
Rimegepant
n=1 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=11 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
Other
|
0 Participants
|
3 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
It only reduces my migraine pain by half
|
0 Participants
|
3 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
It reduces my migraine pain by less than half
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
It does not work quickly enough
|
1 Participants
|
5 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
It does not work as well as it used to
|
0 Participants
|
5 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
The number of side effects I experience
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
The severity of the side effects I experience
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
I am not happy with the way I have to take it
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
I find it difficult to know when to take it
|
1 Participants
|
3 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
I have too many different acute treatments to take
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
I worry about becoming dependent on it
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective)
It costs me too much money
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
Participants responded about their willingness to continue use of acute treatment and responses were classified as definitely yes, probably yes, do not know, probably not, definitely not. Willingness to continue was defined as responses to: 'Definitely yes' or 'Probably yes' combined. Unwillingness to continue was defined as responses to 'Probably not' and 'Definitely not' combined. In this outcome measure number of participants were reported according to participants' responses.
Outcome measures
| Measure |
Rimegepant
n=29 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=94 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective)
Willing to continue
|
28 Participants
|
92 Participants
|
|
Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective)
Unwilling to continue
|
1 Participants
|
2 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure and "Number Analyzed" signifies number of participants evaluable for specified rows.
mTOQ6 was participants reported questionnaire and participants had to respond on following 6 items: 1) "Are you able to quickly return to your normal activities (i.e., work, family, leisure, social activities) after taking your migraine medication?"; 2) "After taking your migraine medication, are you pain free within 2 hours for most attacks?"; 3) "Does one dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours?"; 4) "Is your migraine medication well tolerated?"; 5) "Are you comfortable enough with your migraine medication to be able to plan your daily activities?"; and 6) "After taking your migraine medication, do you feel in control of your migraines enough so that you feel there will be no disruption to your daily activities?". Each item had following responses: never, rarely, less than half the time and half the time or more.
Outcome measures
| Measure |
Rimegepant
n=30 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=109 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 5 · Never
|
0 Participants
|
1 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 1 · Never
|
1 Participants
|
1 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 1 · Rarely
|
1 Participants
|
7 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 1 · Less than half the time
|
1 Participants
|
14 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 1 · Half the time or more
|
27 Participants
|
86 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 2 · Never
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 2 · Rarely
|
2 Participants
|
8 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 2 · Less than half the time
|
1 Participants
|
15 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 2 · Half the time or more
|
27 Participants
|
84 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 3 · Never
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 3 · Rarely
|
1 Participants
|
6 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 3 · Less than half the time
|
2 Participants
|
14 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 3 · Half the time or more
|
27 Participants
|
86 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 4 · Never
|
0 Participants
|
0 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 4 · Rarely
|
1 Participants
|
7 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 4 · Less than half the time
|
0 Participants
|
11 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 4 · Half the time or more
|
29 Participants
|
88 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 5 · Rarely
|
2 Participants
|
10 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 5 · Less than half the time
|
1 Participants
|
14 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 5 · Half the time or more
|
27 Participants
|
83 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 6 · Never
|
0 Participants
|
2 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 6 · Rarely
|
2 Participants
|
5 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 6 · Less than half the time
|
2 Participants
|
17 Participants
|
|
Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6)
Item 6 · Half the time or more
|
26 Participants
|
82 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
In this outcome measure number of participants were classified based on timing/when they took acute treatment as follows: 1) before any sign of a migraine attack, but in anticipation of one starting; 2) at the first sign of a migraine attack (before the pain started); 3) when the pain started; 4) after the pain had started and participant had an idea of pain's severity.
Outcome measures
| Measure |
Rimegepant
n=29 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=104 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Number of Participants Classified Based on Timing They Took Acute Prescription Treatment
Before any sign of a migraine attack, but in anticipation of one starting
|
3 Participants
|
10 Participants
|
|
Number of Participants Classified Based on Timing They Took Acute Prescription Treatment
At the first sign of a migraine attack (before the pain started)
|
21 Participants
|
76 Participants
|
|
Number of Participants Classified Based on Timing They Took Acute Prescription Treatment
When the pain started
|
4 Participants
|
15 Participants
|
|
Number of Participants Classified Based on Timing They Took Acute Prescription Treatment
After the pain has started and participant had an idea of how severe it was
|
1 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Over the last 3 months prior completing the surveyPopulation: Analysis population included all participants who met eligibility criteria was included in this study. Here, "Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.
In this outcome measure mean of number of days per month participants took acute prescription treatment were recorded.
Outcome measures
| Measure |
Rimegepant
n=29 Participants
Participants who in a real world setting under routine clinical practice were prescribed rimegepant for the acute treatment of migraine and their data was observed retrospectively in this study.
|
Triptans
n=108 Participants
Participants who in a real world setting under routine clinical practice were prescribed triptans for the acute treatment of migraine and their data was observed retrospectively in this study.
|
|---|---|---|
|
Mean of Number of Days Per Month Participants Took Acute Prescription Treatment
|
3.29 Days per month
Standard Deviation 1.71
|
4.04 Days per month
Standard Deviation 4.82
|
Adverse Events
Rimegepant
Triptans
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
- Publication restrictions are in place
Restriction type: OTHER